Your browser doesn't support javascript.
loading
Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease.
Abdelmoaty, Mai M; Machhi, Jatin; Yeapuri, Pravin; Shahjin, Farah; Kumar, Vikas; Olson, Katherine E; Mosley, R Lee; Gendelman, Howard E.
Afiliação
  • Abdelmoaty MM; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Machhi J; Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Giza, Egypt.
  • Yeapuri P; Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Shahjin F; Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Kumar V; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Olson KE; Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Mosley RL; Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Gendelman HE; Mass Spectrometry and Proteomics Core, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Clin Transl Med ; 12(7): e958, 2022 07.
Article em En | MEDLINE | ID: mdl-35802825

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Fator Estimulador de Colônias de Granulócitos e Macrófagos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Fator Estimulador de Colônias de Granulócitos e Macrófagos Idioma: En Ano de publicação: 2022 Tipo de documento: Article